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Abstract Amajor challenge in anticancer treatment is the pre-
existence or emergence of resistance to therapy. AXL andMER
are two members of the TAM (TYRO3-AXL-MER) family of
receptor tyrosine kinases, which, when activated, can regulate
tumor cell survival, proliferation, migration and invasion, an-
giogenesis, and tumor-host interactions. An increasing body of
evidence strongly suggests that these receptors play major roles
in resistance to targeted therapies and conventional cytotoxic
agents. Multiple resistance mechanisms exist, including the
direct and indirect crosstalk of AXL and MER with other re-
ceptors and the activation of feedback loops regulating AXL
and MER expression and activity. These mechanisms may be
innate, adaptive, or acquired. A principal role of AXL appears
to be in sustaining a mesenchymal phenotype, itself a major
mechanism of resistance to diverse anticancer therapies. Both
AXL and MER play a role in the repression of the innate
immune response which may also limit response to treatment.
Small molecule and antibody inhibitors of AXL andMER have
recently been described, and some of these have already en-
tered clinical trials. The optimal design of treatment strategies
to maximize the clinical benefit of these AXL and MER
targeting agents are discussed in relation to the different cancer
types and the types of resistance encountered. One of the major
challenges to successful development of these therapies will be
the application of robust predictive biomarkers for clear-cut
patient stratification.
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Introduction
Receptor tyrosine kinases (RTKs) are broadly involved in cel-
lular signaling. Many RTKs are deregulated in cancer, many
of them being oncogenic drivers. The TAM family of RTKs
comprises three transmembrane receptors: TYRO-3, AXL,
and MER. Their extracellular domain resembles to some ex-
tent that of cell adhesion molecules and contains two
immunoglobulin-like and two fibronectin type III domains,
while the intracellular kinase domain mediates activation of
signaling pathways. Activation of the receptors is triggered by
homodimerization following ligand binding, or ligand-
independent mechanisms, such as heterodimerization with
other TAM or non-TAM RTKs. Several ligands have been
identified, with different affinities towards the three TAM re-
ceptors: GAS6, protein S, Tubby, Tubby-like protein 1
(TULP-1), and Galectin-3. More data are available on GAS6
and protein S since they were the first to be identified. GAS6
can bind all three receptors, whereas protein S is specific for
MER and TYRO-3. The affinity of GAS6 is, however, 3- to
10-fold higher for AXL compared to MER and TYRO-3.
In normal adult tissues, TAM receptors have widespread
expression patterns, being expressed in the brain (hippocam-
pus, cerebellum), heart, and liver as well as in monocytes,
platelets, and endothelial cells. Their physiological function
resides mostly in the regulation of inflammation and elimina-
tion of debris via phagocytosis [1••, 2]. Overall, MER is more
specifically expressed by cells from the hematopoietic lineage
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(monocytes, macrophages, dendritic cells, natural killer cells,
platelets) while AXL expression pattern is more constrained to
epithelial tissues.
TAM receptors are implicated in the regulation of the in-
nate immune response as well as in several signaling cascades
that are essential during cancer progression. Being initially
discovered in cancers, their biological functions have mostly
been studied in the oncology field [3, 4]. Overexpression of
AXL and to a lesser extent of MER has been described in
multiple malignancies from epithelial and hematological ori-
gins and is often associated with poor prognosis [1••, 5–9].
Several studies highlight the role of AXL activation in tumor
progression and metastasis development. In most settings,
AXL/MER expression is induced together with the appear-
ance of drug resistance to conventional or targeted therapies
(Table 1). Moreover, AXL expression is associated with epi-
thelial to mesenchymal transition (EMT), a frequent feature of
metastatic tumors often correlated to drug resistance. Both
tumor and stromal cells from the microenvironment can pro-
duce GAS6, fostering a crosstalk between the two cell popu-
lations. Targeting AXL could thus be a good strategy to over-
come drug resistance in multiple cancer types by targeting
both tumor cells (mostly via AXL) and their microenviron-
ment (via AXL and MER).
This review will focus on the role of AXL and MER in
drug resistance and how TAM inhibitors could be best used to
reverse innate or acquired resistance.
Regulation of AXL and MER Expression
Although the mechanisms involved are not fully understood,
the roles of AXL and MER in cancer are governed essentially
by deregulation of transcription leading, directly or indirectly,
to increased levels of the activated proteins [1••, 2, 10]. In the
few cases where chromosome amplifications, mutations or
gene fusions have been described, functional evidence is lack-
ing [11–14]. Mechanisms involved in AXL and MER tran-
scriptional regulation are described below.
Transcription Factors and Regulators
Five transcription factor complexes have been shown to reg-
ulate AXL promoter activity: activator protein 1 (AP1), SP1/
SP3, YAP/TAZ/TEAD, hypoxia inducible factor (HIF), and
myeloid zinc finger 1 protein (MZF-1). Binding sites for the
FOS and JUN components of AP1 are present in the AXL
promoter and functional studies have confirmed their
Table 1 Resistance to
conventional and targeted
therapies involving AXL and
MER
Resistance setting Therapy Cancer type References
AXL-mediated resistance
to targeted therapies
HER2 inhibition Breast [35, 58••]
RAF inhibition Melanoma [84, 121–123, 124]
MEK inhibition Breast, melanoma [63•]
EGFR inhibition NSCLC [60, 82•, 115, 125]




ALK inhibition Neuroblastoma [126, 127]
VEGFR inhibition Diverse [115, 128]
PI3K/AKT inhibition Diverse [61••, 129]
















to immune checkpoint therapies
Breast [97•, 98•]
Colon [99•]
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involvement in the regulation of AXL expression in chronic
myeloid leukemia (CML) and bladder cancer, respectively
[15, 16]. The transcription factors SP1 and SP3 bind to GC-
rich regions on the AXL promoter to induce its expression.
Methylation of CpG sites in these SP binding regions inhibits
SP-driven transcription of AXL [17]. The YAP/TAZ/TEAD
complex was shown to regulate AXL expression in gallblad-
der, hepatocellular carcinoma, and lung cancers [18–20]. In
particular, one study shows that upregulation of the Hippo/
YAP pathway in non-small cell lung cancer (NSCLC) cells
induces AXL expression and leads to increased resistance to
inhibition of the epidermal growth factor receptor (EGFR)
[19]. Interestingly, an association between hypoxia and AXL
has been suggested in clear cell renal carcinoma, where
hypoxia-responsive elements are present in the proximal re-
gion of the AXL promoter and binding of HIF-1 and HIF-2
directly induces AXL expression [21].Moreover, a correlation
between HIF-1 and AXL expression has been shown in met-
astatic prostate cancer, where hypoxia stabilized the AXL pro-
tein [22]. Lastly, one study demonstrates the role of the mye-
loid zinc finger 1 protein (MZF-1) in colorectal and cervical
cancer cell lines [23].
Some studies have highlighted the regulation of AXL tran-
scription in cancer through feedback loops induced by other
RTKs. In NSCLC and head and neck squamous cell carcinoma
(HNSCC) for example, EGFR signaling and downstream
MEK/ERK activation induces expression of AXL mRNA via
the JUN transcription factor [24]. Similar findings have been
described in bladder cancer where AXLmRNA is induced after
MET activation and downstream MEK/ERK signaling [25].
Alternative Transcriptional Control
Two microRNAs (miRNAs) have been described as repres-
sors of AXL expression: miR-34a and miR-199a/b. These
miRNAs bind to the 3′-UTR of the AXL gene to negatively
regulate its expression in breast, colorectal, head and neck,
hepatocellular carcinoma, and lung cancer cell lines [26–31].
Recently, one elegant study showed that the miRNA-
processing enzyme Dicer suppresses AXL expression in
breast cancer cells by inducing expression of miR-494. As a
consequence, cells lose their stem cell-like properties and have
increased sensitivity to paclitaxel [32•].
AXL gene expression is also governed by epigenetic chang-
es in histone acetylation and histone/DNA methylation.
Histone demethylation by EZH2 increases AXL mRNA ex-
pression in glioma [33]. DNAmethylation of AXLwas detect-
ed in NSCLC cell lines and was associated with EMT features
and resistance to EGFR inhibition [34]. Promoter hypomethy-
lation is associated with increased expression of AXL in
HER2 inhibitor-resistant breast cancers [35], acute myeloid
leukemia (AML) [36], and some colorectal models [17].
Histone deacetylase (HDAC) inhibition has been shown to
reduce AXL expression in AML, suggesting a link between
histone acetylation and AXL expression [37]. One study per-
formed in lung cancer cells suggests that mutant p53 could
mediate histone acetylation on the AXL promoter, increasing
AXL expression and triggering cell growth and motility [38].
A more detailed epigenetic map across tumor types and char-
acterization of the methylation/acetylation status of the AXL
gene is required to confirm these findings.
AXL and MER in Resistance Mediated by Feedback
Loops and Receptor Crosstalk
Regulation of AXL and MER Activity
Both paracrine and autocrine loops can activate AXL/MER
signaling cascades (Fig. 1). Multiple studies have shown that
GAS6 is secreted by diverse cell types, from the tumor and/or
stromal cells. To cite a few examples, autocrine activation and
production of GAS6 by tumor cells have been described for
melanoma, GIST, and breast cancers [39–42]. Secretion of
GAS6 from the tumor microenvironment has been shown in
colon, breast, and prostate cancers as well as in AML. In glio-
blastoma, breast cancer, and AML, both autocrine and para-
crine secretion of ligands have been detected [6, 43]. The pro-
duction of GAS6 by stromal cells can create a specific niche in
which AXL signaling cascades are activated and favor metas-
tasis development [44••]. Apart from ligand binding, little is
known as to the regulation of AXL/MER activation. A soluble
form of AXL/MER has been described to negatively regulate
AXL/MER signaling by acting as an antagonist to GAS6 [45,
46]. The C1 domain-containing phosphatase and tensin homo-
log protein (C1-TEN) can dephosphorylate AXL and block
downstream AKT activation [47]. AXL protein can be stabi-
lized by binding to heat-shock protein 90 (HSP90) [48] or
destabilized by ubiquitination by the casitas B-lineage lympho-
ma (CBL) E3 ligases [49, 50]. Interestingly, a downregulation
of CBL has been described as playing a pivotal role in the
resistance of CML to BCR-ABL inhibition [51].
AXL and MER Downstream Signaling Pathways
Like most RTKs, AXL and MER transmit signals into the cell
via adaptor proteins. Importantly, the binding of adaptor pro-
teins to phosphorylated AXL/MER appears to be context- and
tissue-specific. It is thus important to understand the disease-
specific phenotype in order to decipher in which signaling
networks AXL and MER play a role. Activation of AXL/
MER by ligand binding triggers receptor dimerization and
subsequent autophosphorylation of their cytoplasmic domain
[1••]. Each phosphorylated tyrosine residue (Tyr) serves as a
docking site for specific adaptor proteins. Five phosphoryla-
tion sites have been described for MER: Tyr749, Tyr753,
Curr Oncol Rep (2017) 19: 19 Page 3 of 14 19
Tyr754, Tyr872, and Tyr929. The last two mediate binding to
GRB2 and the p85 regulatory subunit of PI3K, which activate
MEK/ERK and PI3K/AKT signaling pathways, respectively.
Six phosphorylation sites have been identified in AXL:
Tyr698, Tyr702, Tyr703, Tyr779, Tyr821, and Tyr866.
While the three more N-terminal residues are putative auto-
phosphorylation sites reflecting AXL activation, the three
most C-terminal tyrosines are docking sites for downstream
effector proteins [52]. Phospho-Tyr779 and phospho-Tyr821
bind to p85 and activate PI3K/AKT signaling; binding of
GRB2 to phospho-Tyr821 transduces theMEK/ERK cascade;
phospho-Tyr821 and phospho-Tyr866 bind to SRC, LYK, and
PLCγ which can switch on additional signaling networks
such as PKC or STAT [53–56] (Fig. 1).
Direct Roles of AXL and MER Signaling in Resistance
AXL expression can circumvent resistance to targeted agents
and specifically to inhibitors of other RTKs by either main-
taining activity of the same pathway via alternative effectors
or by inducing activation of distinct signaling networks. For
instance, in NSCLC and HNSCC models, AXL expression
sustains PI3K/AKT and MEK/ERK signaling and thus medi-
ates resistance to the EGFR inhibition [24, 57]. A positive
feedback loop further reinforces this bypass mechanism in
which the MEK/ERK pathway induces transcription of AXL
by JUN [24]. Moreover, AXL can dimerize with non-TAM
receptors, such as EGFR, MET, and PDGFR [25, 58••, 59, 60,
61••]. This crosstalk triggers a signaling switch, leading to the
bypass of the RTK inhibitor effect. An elegant study in triple-
negative breast cancers demonstrated that AXL binds to
EGFR, other ErbB receptors, MET, and PDGFR depending
on their expression levels and membrane localization [58••].
Similarly, dimerization of AXL and HER3 has been shown to
bypass HER2 signaling inhibition by lapatinib in breast cancer
cells [35]. In squamous cell carcinoma resistant to PI3K in-
hibitors, dimerization of AXL with EGFR activates the
PLCγ/PKC/mTOR pathway to sustain tumor progression
[61••], and in mesenchymal ovarian tumors and cell lines,
AXL dimerized with MET, EGFR, and HER2, leading to
sustained ERK activation [62•]. Switching between receptors
is another escape mechanism that has been described in
gastro-intestinal stromal tumors (GIST). Cells resistant to the
KIT/PDGFR inhibitor imatinib express lower levels of KIT
while upregulating AXL and GAS6 [39]. Finally, a recent
study has very elegantly shown that inhibition of the MEK/
ERK pathway decreases the proteolytic shedding of AXL
from the surface of melanoma and breast cancer cells, thus
removing negative feedback on its signaling activity [63•].
Indirect Roles of AXL and MER in Resistance via Tumor
Cell Proliferation, Survival, Migration, and Invasion
As described above, activation of AXL or MER initiates sig-
naling cascades that are essential for tumor progression.While
regulation of cell proliferation is mostly mediated by
Fig. 1 AXL and MER signaling
networks in tumor cells.
Schematic representing the major
signaling networks activated
upon binding of GAS6 with its
TAM receptor in tumor cells.
Affinity of GAS6 for AXL is
higher than that for MER.
Tyrosine docking sites in AXL
are represented. Diverse adaptor
proteins mediate activation of
specific signaling pathways,
involved in proliferation,




markers) are indicated by yellow
stars. Crosstalk between AXL
and other RTKs is exemplified by
the dimerization with EGFR and
MET. Signaling implicated in the
regulation of the immune
response is depicted by blue
arrows
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activation of the p38- and MEK-driven MAPK signaling cas-
cades, most of the published work suggests a more prominent
role of AXL in the PI3K/AKT/mTOR and JAK/STAT path-
ways in tumor cell survival [1••, 2, 10, 64] (Fig. 1). In partic-
ular, activation of AKT leads to the nuclear translocation of
NF-kB which induces expression of anti-apoptotic proteins,
such as survivin, BCL2, BCL-XL, and cyclinD1, as well as
phosphorylation and inhibition of the pro-apoptotic protein
BAD [10, 65–67]. As a consequence, inhibition of AXL/
MER can induce apoptosis in tumor cells via blocking both
MEK/ERK and PI3K/AKT pathways [68]. One study in
chronic lymphocytic leukemia (CLL) also suggested that
AXL inhibition mediates apoptosis by reducing the expres-
sion of the anti-apoptotic protein MCL1 [54]. Induction of
the PLCγ-PKC signaling cascade by AXL leads to
mTORC1 activation, which also promotes cell survival
[61••] (Fig. 1). In addition, interplay between receptors of
the TAM family can modify the signaling outcome induced
by GAS6 [69]. Interestingly, one study suggests that the bal-
ance between AXL and TYRO-3 expression is important in
the dormancy of prostate cancer cells, with high TYRO-3
levels promoting proliferation and high AXL expression lead-
ing to a quiescent phenotype [70].
Besides regulating proliferation and survival, AXL pro-
motes cell migration, cell invasion, and metastasis develop-
ment in several cancer types [7, 8, 71–73]. The induction of
such a migratory phenotype is mediated by AKT and SRC
pathways as well as RAC-induced cytoskeleton changes [74,
75]. It was also proposed that the kinase domain of AXL can
bind to the actin cytoskeleton while the extracellular domain
of the receptor modulates cell adhesion by regulating the ex-
pression of tight- and adherent-junction proteins [76].
Together, these observations strongly suggest that the increase
of AXL/MER activity typically observed following conven-
tional or targeted therapy will lead indirectly to drug resistance
via marked promotion of tumor progression and aggressive-
ness (Table 1).
AXL and MER in Resistance Mediated
by Epithelial-to-Mesenchymal Transition
The Importance of EMT in Resistance
Epithelial-to-mesenchymal transition, or EMT, corresponds to
the reversible conversion of epithelial cells to mesenchymal
cells, and plays an important role during embryonic develop-
ment and wound healing. EMT involves profound phenotypic
changes that include loss of epithelial characteristics with con-
comitant acquisition of mesenchymal traits, the latter being
more appropriate for migration and invasion. In the cells that
undergo EMT, typical epithelial markers, such as E-cadherin
and cytokeratins, are repressed while mesenchymal
markers, such as N-cadherin, vimentin, or fibronectin,
are induced. A number of transcription factors are well
described as EMT inducers: SNAI1/2, TWIST1/2, and
ZEB1/2. EMT is also associated with modifications in
matrix composition and matrix adhesion proteins that
will contribute to enhance cell migration in the stromal
compartment [77]. Due the plasticity of cells required
during the invasion cascade, multiple studies have
shown an association between EMT and metastasis de-
velopment [78].
The loss of epithelial features by mesenchymal cells
is very often correlated with induction of stem cell-like
properties, such as decreased proliferation and as a con-
sequence, increased resistance to anti-proliferative agents
[79]. In this way, cells that are intrinsically mesenchy-
mal or that have undergone an EMT show higher degree
of resistance to chemotherapeutic agents as well as to
targeted therapies [80•]. Interestingly, a recent study in
mesenchymal NSCLC, TNBC, and HNSCC cell lines
very elegantly demonstrated that the reversal of EMT
by AXL inhibition was accompanied by decreased ex-
pression of DNA repair genes, diminished efficiency of
homologous recombination and sensitivity to poly
(ADP-ribose) polymerase (PARP) inhibition, leading to
apoptotic cell death [81••].Together, these studies show
that EMT can be considered a major, albeit indirect,
mechanism of drug resistance [82•].
AXL as a Sustainer and Effector of EMT
The implication of AXL in EMT is supported by a mul-
titude of studies, which frequently highlighted a correla-
tion between AXL expression and features of EMT [77,
80•, 83]. Expression of AXL is upregulated in mesen-
chymal EMT-like cells, suggesting a role of AXL in this
phenotypic transition. In addition, AXL scores as one of
the top genes in EMT-specific signatures [44••, 82•, 84•].
AXL expression enhances migratory capabilities of can-
cer cells and is often associated with increased metastasis
development and poor prognosis. However, whether
AXL induces EMT or whether EMT induces AXL ex-
pression remains an open debate. More mechanistic data
on their causal relationship are warranted to address this
point.
Inhibition of AXL by small molecule inhibitors or depletion
of AXL by siRNA has been shown to reverse resistance of
mesenchymal cancer cells, without necessarily switching them
back to an epithelial state. These findings support the fact that
AXL is required to maintain EMT-driven drug resistance, but is
not necessarily the cause of the mesenchymal state itself [10,
44••,85]. Indeed, several reports pinpoint AXL as a downstream
effector of EMT. Most available data are focused on breast can-
cer, where SNAI1/2 transcription factors induce AXL
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expression together with regulation of the expression of key
EMT genes [42, 86]. An EMT gene signature, which includes
high levels ofAXL, has been described as a predictive biomarker
of resistance to EGFR or PI3K inhibitors in several solid tumors.
However, in this context, inhibition of AXL by a small molecule
inhibitor was sufficient to reverse EMT-associated resistance
[82•]. Supporting this finding, a kinome-wide shRNA screen
also identified AXL as a key regulator of the mesenchymal state
and stem cell properties in glioblastoma [87]. A similar study in
breast cancer models demonstrated a role of AXL in the main-
tenance of stemness and further showed that AXL downregula-
tion could reverse the EMT phenotype of the cancer stem cell
population [88]. A number of mechanistic studies also support
the hypothesis that AXL is indeed an EMT inducer. AXL was
shown to control the expression of the transcription factors
SNAI1/2 and TWIST1/2 in pancreatic cancer [89] and, in breast
cancer, to activate the AKT/GSK3β/β-Catenin cascade that in-
duces expression of ZEB1 and other EMT-related genes [90]. A
similar study performed in head and neck cancer suggests that
resistance to the EGFR inhibitor erlotinib is associated with low
miR34a and high AXL levels, the latter inducing EMT via the
AKT pathway [28].
In conclusion, the causal connection between AXL and
EMT is likely to be context- and tissue-specific. Since several
reports have clearly highlighted the therapeutic value of
inhibiting AXL/MER signaling cascades, AXL/MER recep-
tors are likely not solely biomarkers of the mesenchymal phe-
notype and drug resistance but rather have a functional role in
maintaining this drug tolerant state.
AXL andMER inResistanceMediated by the Tumor
Microenvironment
Role of AXL and MER in the Innate Immune Response
Besides the oncogenic signaling networks described in
the previous sections, AXL and MER play important
roles in the innate immune system by promoting phago-
cytosis of apoptotic cells and debris, supporting the mat-
uration of natural killer cells (NK cells) and inhibiting
inflammation driven by dendritic cells (DCs) and macro-
phages [1, 91, 92•]. Here, the functions of AXL and
MER as regulators of inflammation are discussed in the
context of their role in the immune response to cancer
and resistance to anticancer treatment.
In inflammatory conditions, type I interferon (IFN) binds
the IFNα receptors (IFNAR) on DCs to amplify the inflam-
matory response through activation of the JAK/STAT1 path-
way, leading to the transcription of pro-inflammatory cyto-
kines. AXL and MER have been shown to bind the IFNAR
and redirect downstream signaling via STAT1 to activate tran-
scription of the suppressor of cytokine signaling (SOCS)
proteins which inhibit JAK [92•]. Thus, AXL/MER activation
mediates a negative feedback loop in order to dampen the
inflammation process and avoid tissue damage. Furthermore,
activation of the TAM receptors in macrophages leads to a
switch from a M1 to a M2 phenotype, the latter being unable
to activate CD8 positive T cells [93]. As a consequence, acti-
vated TAM receptors in tumors induce immunosuppression
which blocks the antitumor activity of cytotoxic T cells. In
such an environment, the efficacy of anticancer treatment is
decreased and resistance can develop. Supporting this hypoth-
esis, a high level of M2 macrophages in tumors often corre-
lates with poor prognosis. On contrary, inhibition of TAM
receptors maintains macrophages in a M1 state, in which they
secrete pro-inflammatory cytokines and can activate T cells
[1••, 94, 95•].
Taking this role of AXL/MER into account, blocking their
activity could improve antitumor response by (i) increasing
pro-inflammatory cytokines and antitumor activity of cytotox-
ic T cells in tumors with an immunosuppressive environment
(high M2 macrophages, low levels of activated CD8 T cells),
(ii) simultaneously targeting tumor cells and macrophages in
resistant AXL/MER-positive tumors, and (iii) combining
TAM inhibitors with immunotherapies to improve antitumor
T cell activity by blocking inhibitory checkpoints (e.g., anti-
PD1 or anti-CTL4A). In support of this approach, a recent
study by Hugo et al. in metastatic melanoma demonstrated
that innate resistance to anti-PD1 therapies was associated
with overexpression of AXL and an increased number of in-
filtrated macrophages [96••]. Of note, three recent studies in
mouse syngenic models of colon and breast cancer showed
marked synergy for tumor growth inhibition with dual inhibi-
tion of AXL and PD1 or CTLA4 [97•, 98•, 99•]. Incidentally,
a combination of AXL/MER inhibition with immunotherapies
may be of particular importance in tissues where inflammation
could have a tumor-promoting function, as is the case of colon
cancer [100].
In conclusion, these findings suggest that AXL/MER in-
hibitors could have an important tumor immunomodulatory
role, causing a switch from an anti-inflammatory and immu-
nosuppressive context (M2 macrophages) to a pro-
inflammatory and immuno-active milieu (M1 macrophages,
activated T cells). Immunoprofiling of patient tumors pre- and
post-treatment and its correlation with TAM expression as
well as more detailed preclinical studies in immunocompetent
models are required to validate this hypothesis.
Role of AXL and MER in Angiogenesis
Another function of TAM receptors resides in vascular integ-
rity and pro-angiogenic properties. During wound healing or
vasculature damage, TAM receptor signaling promotes stabi-
lization of platelet aggregation, survival of endothelial cells,
and restitution of the endothelial barrier function [92•,
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101–103]. Being expressed by endothelial cells, TAM recep-
tors participate in the formation of new vessels and contribute
to their stabilization via signaling in AXL-positive vascular
smooth muscle cells. In particular, AXL has been described as
a key modulator of endothelial cell functions that are required
for angiogenesis and tumor growth [104]. Both autocrine and
paracrine loops between AXL and its ligands GAS6 promote
motility and proliferation of endothelial cells, modulate
integrin function to facilitate migration and survival of endo-
thelial and tumor cells, and facilitate cell motility via regula-
tion of RAC and AKT pathways. In this context, activation of
AXL and MER on endothelial cells has been proposed as a
means of resistance to antiangiogenic therapies targeting the
vascular endothelial growth factor (VEGF) and fibroblast
growth factor (FGF) receptors [102, 103, 105]. A recent phase
III clinical study of cabozantinib—which inhibits AXL in ad-
dition to MET and VEGFR—in renal cell carcinoma (RCC)
patients progressing after VEGFR inhibitor treatment, sup-
ports the hypothesis that AXL inhibition could target resis-
tance to VEGFR inhibition [106].
Targeting AXL and MER in the Clinic
Optimal Therapeutic Strategies as a Function of Cancer
Type and Resistance Mode
Overall, based on the current evidence, it seems that AXL and
MER have a limited role to play in cancer initiation and pro-
gression per se. AXL/MER overexpression seems to be large-
ly restricted to cells that are or have become refractory to
anticancer treatments, where their roles in cancer cell prolifer-
ation, survival, migration, invasion, and EMT provide a strong
rationale to block their activation in order to reverse the drug
tolerant state and overcome resistance. AXL/MER inhibitors
could thus be used in two distinct scenarios, as modulators of
either innate or acquired resistance.
Some cancers have intrinsically high AXL orMER expres-
sion. Studies suggesting a role of AXL and MER in leukemia
cells led to a phase I clinical trial of the specific AXL inhibitor
BGB324 as a monotherapy in AML in which signs of clinical
benefit were seen [107••]. Studies on treatment-naive colon
and breast cancers have described mesenchymal subgroups
with high AXL expression, suggesting that targeting of AXL
in these specific patient populations could be beneficial, pos-
sibly as a monotherapy or, more likely, to reverse innate resis-
tance to conventional and targeted therapies [108•, 109, 110].
However, a wider benefit of AXL/MER inhibitors is likely to
be for patients with acquired resistance to conventional or
targeted therapies, where AXL/MER inhibitors would be used
in combination with the agent to which resistance was devel-
oped. Preclinical and clinical studies that form the basis of the
different rationales for these combinations are summarized in
Table 1; some are described in more detail in the preceding
sections. Several clinical trials are currently evaluating the
potential of AXL/MER inhibitors in these settings [10, 111•,
112]. Finally, the immunosuppressive and pro-angiogenic
functions of TAM receptors place them as attractive targets
for the tumor stroma. Indeed, inhibition of TAM could create
an immune proficient niche and favor activation of cytotoxic
T cells. Blocking AXL signaling could also reduce angiogen-
esis and tumor growth [105]. Hence, AXL/MER inhibitors
could have a dual function by targeting both tumor cells and
their stroma. However, careful toxicity evaluation should be
done as chronic exposure to TAM inhibitors, particularly
MER, may cause autoimmune disorders. There is, nonethe-
less, a certain degree of redundancy in the roles of the TAM
receptors in immune suppression. The development of specif-
ic AXL inhibitors with lower affinity for either MER or
TYRO-3 could thus be useful to avoid these potential side
effects [1••, 92•].
Small Molecule AXL and MER Inhibitors in Preclinical
and Clinical Development
Three strategies have been developed to inhibit TAM activity
by (i) blocking ligand/receptor binding with antibodies, (ii)
inhibiting kinase activity with ATP competitors, and (iii) re-
ducing TAM expression [111•]. Anti-AXL monoclonal anti-
bodies and an aptamer approach have been described but these
two strategies have not been well documented so far [105,
113–116]. The second strategy, which is commonly used for
RTK inhibition, has led to several ATP-competitive com-
pounds [10, 111•, 112].
Many of these molecules are multi-kinase inhibitors, for
which AXL is not the main target and that were not initially
developed to block its activity (Table 2). So far, only three
molecules are described as specific AXL inhibitors: the first-
in-class compound BGB324 which has entered clinical trials
and TP-0903 and SLC-0211 still at preclinical stage. The lack
of specificity of some of the other molecules may nevertheless
be used as an advantage for anticancer treatment as multiple
RTKs are involved in tumor progression and disease recur-
rence. Due to the similarity of the ATP binding site between
MET and AXL, many of the compounds target these two
receptors. As METand AXL are involved in resistance mech-
anisms, especially in NSCLC, inhibiting both simultaneously
may target distinct resistant populations within the same tu-
mor, or prevent the emergence of secondary mechanisms of
resistance, and thus be highly beneficial for patients. In this
context, monotherapy trials of the multi-kinase inhibitors
Cabozantinib, Sitravatinib, and Glesatinib are specifically in-
cluding NSCLC patients with high expression or genetic ab-
errations of AXL. However, based on the preclinical hypoth-
eses outlined in this review, it may be necessary to combine
with the agent to which resistance has developed to observe
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clinical benefit. Moreover, the fact that these multi-kinase in-
hibitors also target angiogenesis via inhibition of VEGFR2
will further confound the issue. The interpretation of the re-
sults of these trials will thus have to be made with caution in
terms of any possible link between antitumor efficacy and
high AXL expression. Results of the phase I/II NSCLC trials
of the more selective Gilteritinib and BGB324 (no specific
patient selection) and S49076 (including patient selection
based on high AXL expression) in combination with EGFR
inhibition are eagerly awaited. BGB324 is also being investi-
gated in combination with docetaxel in NSCLC.
Challenges in Identifying Pharmacodynamic
and Predictive Biomarkers
The signaling cascades activated downstream of AXL/MER
are dependent on the tissue context. These complex signaling
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networks have been a challenge for the identification of robust
biomarkers of (i) AXL/MER activity and (ii) response to
AXL/MER inhibition. Moreover, the discrepancy between
the possible readouts proposed in different in vitro studies is,
in part, due to the lack of robust relevant in vitro models to
study AXL/MER cellular functions. Indeed, their activity is
tightly regulated by interaction with their ligands, which may
require the presence of stromal cells and/or a particular orga-
nization of tumor cells. More complex 3D co-culture systems
may resolve this issue. So far, molecular data are mostly avail-
able on AXL rather than MER as it is the most commonly
studied and targeted TAM receptor.
Pharmacodynamic Biomarkers
Levels of expression and activation of AXL in patient tumors
are currently assessed by immunohistochemistry analysis of
total protein and phosphorylation status of the receptors as
well as expression of GAS6. The phosphorylation of the
Tyr702 site, for which good antibodies are available, is com-
monly used as a marker of AXL activation.
The identification of a robust pharmacodynamic (PD)
marker for direct target hitting has been challenging, largely
due to the fact that there are no good commercially available
antibodies to the autophosphorylation sites (Tyr779, Tyr821,
and Tyr866). Interestingly, while some of the less selective
AXL inhibitors may also indirectly lead to a marked reduction
in phosphorylation of the Tyr702 site [117], more selective
inhibitors such as BGB324 and S49076 do not [118, 119].
The implications of these different patterns of inhibition of
the phosphosites in terms of downstream signaling remain to
be determined. Good and specific antibodies for each docking
site are also lacking, which precludes a precise molecular
analysis of AXL phosphorylation status.
The activation of multiple signaling cascades, togeth-
er with the fact that many if not all of these pathways
are also downstream of other RTKs, excludes the use of
phosphorylation of downstream molecules such as AKT.
It is possible, however, that further insight into the im-
pact of AXL-specific compounds on signaling via in
depth phospho-proteomic studies would provide useful,
specific, PD biomarkers.
Predictive Biomarkers of Response
The expression levels of AXL, and to a lesser extent GAS6,
are described as broad markers of poor prognosis [6, 120]. In
AXL-driven clinical trials, AXL and GAS6 expression levels
are used to select AXL-positive populations. What threshold
of AXL/GAS6 expression or whether a specific molecular
context is associated with a better clinical response is still an
open question. The comparison of responders and non-
responders from the ongoing BGB324 and S49076 clinical
trials will likely be very informative.
Conclusion
Resistance to conventional and targeted therapy is a major
cause of failure of anticancer treatment. Further understanding
of resistance mechanisms and identification of specific targets
driving this resistance will allow development of compounds
able to selectively kill the drug tolerant population and avoid
disease recurrence. TAM receptors, in particular AXL, have
emerged as key mediators of innate and acquired drug resis-
tance in multiple cancer types, from both hematological and
epithelial origins. As a consequence, several multi-kinase in-
hibitors have been repurposed to target AXL in the clinic to
reverse resistance. Importantly, the role of AXL in dampening
the immune response has led to promising novel therapeutic
strategies combining AXL targeting compounds with immune
checkpoint inhibitors. In conclusion, AXL has become an
attractive target for anticancer treatment, most specifically in
combination. More AXL-specific inhibitors are now being
developed and will hopefully provide novel strategies to over-
come drug resistance using well-tolerated drugs capable of
being used in combination. The identification of robust bio-
markers of activity and response for these novel molecules
will be required for appropriate patient stratification and opti-
mal clinical benefit.
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